.jpg)
.png)
Top Stories
Further results from the two phase 3 trials of the omega-3 fatty acid product ethyl eicosapentaenoic acid (EPA) (AMR101, Amarin), which showed the agent reduced triglycerides without increasing low-density lipoprotein (LDL) and reduced the number of atherogenic particles, were presented last week... more
Amit Khera, M.D., Saskia Neher, Ph.D., each earn two-year grant for lipid disorder research NLA Junior Faculty Research Award Information JACKSONVILLE, Fla. — The National Lipid Association (NLA) announced on Thursday the recipients of its inaugural Junior Faculty Research Awards for... more
Novartis announced that the U.S. Food and Drug Administration (FDA) approved Leqvio (inclisiran) as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH... more
When Kennedi Thompson started developing xanthomas – fatty deposits that appear as white, raised bumps on the skin – her parents initially thought she was having an allergic reaction. Fox News - January 18, 2012
Jacksonville, Florida - (August 25, 2022) - The American College of Cardiology (ACC) announced the release of the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of... more
Heart disease is the biggest killer in the country. But an argument is raging about a popular way of preventing it. Wall Street Journal - January 23, 2012
In >95% of patients, high triglycerides reflect the burden of the effects of more than 30 genes involved in triglyceride pathways Published in Lancet Diabetes & Endocrinology,1 Free to download from 31 January – 28 February 2014 at http://www.thelancet.com/journals/landia/article/... more
JACKSONVILLE, Fla. -- The National Lipid Association announced Monday it has united with MD Magazine®, a leading online and print source of physician news, conference coverage, and peer-to-peer discussion, through Michael J. Hennessy Associates' Strategic Alliance Partnership (SAP) Program... more
Are you excited for a new year with the NLA? While we still have so much to accomplish in 2022, there is a lot of excitement about what we will be doing as we head into 2023. The NLA has developed a series of educational activities and engagement opportunities for our members and those interested... more
A few weeks ago, FDA announced that cholesterol-lowering drugs known as statins would have to carry warnings that side effects can include, among other things, possible memory loss. WebMD, April 2, 2012